GammaCan Receives FDA Orphan Drug Designation for VitiGam

GammaCan announced its lead anticancer immunotherapy, VitiGam, has received orphan drug designation from the FDA for the treatment of Stage IIB to Stage IV metastatic melanoma.

GammaCan said it anticipates initiating clinical testing of VitiGam in early 2008.

VitiGam is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition, the company added.